A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults☆
Vaccine(2016)
Abstract
•Largest controlled safety study of a recombinant meningococcal serogroup B vaccine.•SAEs occurred in lower percentage of bivalent rLP2086 group than control group.•SAEs related to vaccine were rare.•Rates of medically-attended AEs were similar between vaccine groups.•Bivalent rLP2086 was safe and tolerable in adolescents and young adults 10–25 years.
MoreTranslated text
Key words
AE,fHBP,HAV,IMD,MAE,MnB,NDCMC,SAE
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined